Loading
A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Phoenix Molecular Designs, active and no longer recruiting.
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT04115306 by Phoenix Molecular Designs, with 61 participants enrolled, started 2019-11-14 and due to reach its primary completion in 2026-12. Interventions recorded: PMD-026 and fulvestrant.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.